RetiSpec

📍 Toronto, Canada🗓 Founded 2016👥 31 employees💰 Last funded Sep 2018
Software Development🌐 retispec.ai
Website LinkedIn
RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpecs proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimers disease. RetiSpec is involved in multiple Alzheimers and brain health studies in leading hospitals and research networks throughout North America. RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimers disease and other causes of cognitive decline. RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimers Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in RetiSpec?
RetiSpec has 2 investors on record on gritt.io, including 2 early-stage backers.
When did RetiSpec last raise funding?
The most recent investment in RetiSpec recorded on gritt.io was in September 2018.
When was RetiSpec founded?
RetiSpec was founded in 2016.
What industry is RetiSpec in?
RetiSpec operates in Software Development. Find similar Software Development investors on gritt.io.
Where is RetiSpec based?
RetiSpec is headquartered in Toronto, Canada.